requiring medical assistance (DC= 6.0, DT= 5.9), HE requiring non-medical assistance (DC= 5.9, DT= 5.9), other HE not requiring assistance (DT= 5.7), and treatment goals not being met (DC= 5.6). Compared to current users, DT and DC patients were more likely to have experienced ≥ 1 HE in the previous year (DC= 41.0%, DT= 43.1% vs. current= 8.8%; p< .05), and experienced a greater mean number of events per year (DC= 1.59, DT= 1.47 vs. current= 0.24, p< .05). Having ≥ 1 HE requiring medical assistance in the previous year was more common among DC patients than DT or current patients (DC= 7.4%, DT= 4.3%, current= 4.8%; p< .05). CONCLUSIONS: Hypoglycemia and glycemic control emerged as the most important concerns physicians have when deciding to DC or DT SU therapy. DC and DT patients were more likely to have experienced HE, and with greater severity, than current SU patients. OBJECTIVES: While change in glycated hemoglobin (A1C) is typically used as the primary measure of efficacy in clinical trials of diabetes medications, quality of care in "real-world" clinical practice is often assessed based on attainment of patientspecific A1C targets, as recommended in HEDIS 2014 performance benchmarks by the National Committee for Quality Assurance. HEDIS measures are used by US health plans to measure care and service performance. To assist in the design of pragmatic clinical trials for new insulin glargine 300 U/ml (Gla-300), we estimated A1C targets for T2DM patients initiating basal insulin in real-world clinical practice, using a large retrospective database and data from a clinical trial. METHODS: Insulin-naïve T2DM patients initiating basal insulin were identified in both the Ingenix Impact National Managed Care (IMPACT) database (n= 22,428) and EDITION 3 (n= 862), a clinical trial of Gla-300. Patients were stratified according to whether they were aged < 65y and free of selected comorbidities (A1C target < 7.0%), or aged ≥ 65y and/or with one or more comorbidities (A1C target < 8.0%), according to HEDIS measures. RESULTS: In the IMPACT database, mean age was 52y, and mean baseline A1C (SD) was 9.0% (±2.7) in those with available A1C. Patients aged < 65y without comorbidities (target < 7.0%) constituted 68.1% of the sample, while 31.9% were aged ≥ 65y and/or had comorbidities (target < 8.0%). In the EDITION 3 trial, mean age was 58y, and mean baseline A1C (SD) was 8.5% (±1.1). Patients aged < 65y without comorbidities (target < 7.0%) constituted 73.0%, and 27.0% were aged ≥ 65y and/or had comorbidities (target < 8.0%). CONCLUSIONS: The distribution of T2DM patients initiating basal insulin by A1C target, based on HEDIS performance measures, was similar in both real-world and clinical trial settings. Findings from trials therefore may be useful in the design of pragmatic clinical trials of Gla-300.
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Use of HeDis a1c TargeTs in cHaracTerizing TreaTmenT goals in PaTienTs wiTH TyPe 2 DiaBeTes melliTUs (T2Dm) iniTiaTing Basal insUlin
OBJECTIVES: While change in glycated hemoglobin (A1C) is typically used as the primary measure of efficacy in clinical trials of diabetes medications, quality of care in "real-world" clinical practice is often assessed based on attainment of patientspecific A1C targets, as recommended in HEDIS 2014 performance benchmarks by the National Committee for Quality Assurance. HEDIS measures are used by US health plans to measure care and service performance. To assist in the design of pragmatic clinical trials for new insulin glargine 300 U/ml (Gla-300), we estimated A1C targets for T2DM patients initiating basal insulin in real-world clinical practice, using a large retrospective database and data from a clinical trial. METHODS: Insulin-naïve T2DM patients initiating basal insulin were identified in both the Ingenix Impact National Managed Care (IMPACT) database (n= 22,428) and EDITION 3 (n= 862), a clinical trial of Gla-300. Patients were stratified according to whether they were aged < 65y and free of selected comorbidities (A1C target < 7.0%), or aged ≥ 65y and/or with one or more comorbidities (A1C target < 8.0%), according to HEDIS measures. RESULTS: In the IMPACT database, mean age was 52y, and mean baseline A1C (SD) was 9.0% (±2.7) in those with available A1C. Patients aged < 65y without comorbidities (target < 7.0%) constituted 68.1% of the sample, while 31.9% were aged ≥ 65y and/or had comorbidities (target < 8.0%). In the EDITION 3 trial, mean age was 58y, and mean baseline A1C (SD) was 8.5% (±1.1). Patients aged < 65y without comorbidities (target < 7.0%) constituted 73.0%, and 27.0% were aged ≥ 65y and/or had comorbidities (target < 8.0%). CONCLUSIONS: The distribution of T2DM patients initiating basal insulin by A1C target, based on HEDIS performance measures, was similar in both real-world and clinical trial settings. Findings from trials therefore may be useful in the design of pragmatic clinical trials of Gla-300.
PDB101 effecT of DiaBeTes eDUcaTion Program on TyPe 2 DiaBeTes
Younis M. Jackson State University, New Orleans, LA, USA OBJECTIVES: The aim of the study was to measure the effect of diabetes educational program on type 2 diabetic patients. METHODS: In total, a convenient sample of 215 patients were attended a group-based educational intervention session about diabetes which is conducted by a researcher. Knowledge evaluation questionnaire were evaluated at pre and post test. Anthropometric measurements and lab tests were measured at pre and post test. Significance of the results was assessed by paired t-test at 95% confidence interval using SPSS version 16. RESULTS: BMI was decreased significantly after educational intervention, (from 32.1±5.76 to 31.23±5.8) (p = 0.000). Moreover, a significant decrease in glycosylated hemoglobin after educational intervention were reported, (from 8.57± 1.21 to 7.95±1.42) (p = 0.000).A significant increase in knowledge evaluation test scores were shown after educational intervention (from 60.6±20.65 increased to 78.1±13.4) (p = 0.000). CONCLUSIONS: Diabetes education is a cornerstone in the management and care of diabetes and should be an integral part of health planning involving patient's family, diabetes care team, community and decision makers in the education process.Key words Diabetes, Educational, Program, Intervention.
PDB102 cHanges in Baseline comorBiDiTies, meDicaTions anD HealTHcare cosTs for a PoPUlaTion of PaTienTs wiTH new-onseT TyPe 2 DiaBeTes (T2D) in 2007 comPareD wiTH 2012
Weng W. , Liang M. , Kimball E. , Hobbs T. , Kong S. , Bouchard J. , Sakurada B. Novo Nordisk, Inc., Plainsboro, NJ, USA OBJECTIVES: It is important to understand diabetes treatment patterns over time. This study compared changes in comorbidities, treatment patterns, and costs among newly-diagnosed T2D patients in 2007 and 2012. METHODS: Separate cross-sectional analyses of medical treatments, diagnoses, and pharmacy claims in the Truven Health MarketScan® Database were conducted for 2007 and 2012. Criteria for newly-diagnosed T2D were enrolment 6 months prior to index, ≥ 2 diagnoses for T2D (ICD-9 codes), ≥ 18 years old, and continuous enrolment in a plan with prescription benefits for ≥ 1 year. RESULTS: Comparing 2007 with 2012, T2D incidence rate decreased from 1.1% to 0.65% of all enrolled patients. Hyperlipidemia (46% and 57%) and hypertension (55 % and 62%) were the 2 most prevalent comorbidities. 46% and 57% of patients in 2007 and 2012 used only oral anti-diabetic drugs (OADs). Single OAD use increased from 68% to 77% of these patients. Metformin (Met) was the most prevalent OAD monotherapy, amounting to 75% and 90% of single OAD prescriptions. SU monotherapy fell from 14% to 6%. Met+SU, the most widely used dual OAD combination, grew from 48% to 57% of dual users. Met+TZD use fell from 30% to 0%, replaced by Met+DPP-IV (34%). An insulin-only regimen was used by 1.4% and 1.6% of patients for 2007 and 2012, and insulin+OADs were used by 2.5% and 3.7% of patients, respectively. Basal OBJECTIVES: Women with Gestational Diabetes Mellitus (GDM) have six times higher risk of developing Diabetes Mellitus (DM) type 2 compared to women who don't have GDM. The purpose of this study was to evaluate the protective effects of breast-feeding on development of DM in women with GDM. METHODS: This was a cross sectional study where a secondary database analysis was done using National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010 and 2011-2012 . Females 20 to 75 years with at least one live birth were included. Chi-square-test compared differences between categorical variables and t-test examined differences in the means for continuous variables. Unadjusted-odds-ratio was calculated using logistic regression to examine breastfeeding as an effect modifier in the association between GDM and DM. Model was adjusted for age, BMI, race/ethnicity, income, education, age at DM and number of live births. Sample weights and the stratification and clustering of the design were incorporated to obtain proper estimates. RESULTS: The final analytic sample consisted of 6503 participants. Percentage of GDM women who breast-fed seemed higher than women without GDM (64.6 % vs. 44.9%). Among women who breastfed, the odds ratio for developing DM in women with GDM was 3.3 (95% CI 2.3, 4.9) compared to those without GDM while, in women who never breastfed, the odds ratio was 3.9 (95% CI 2.3, 6.6). After adjusting for age, BMI, race/ ethnicity, education and number of live births, OR for the association between DM and GDM was 2.2 (1.4, 3.4) in women who breastfed and 2.8 (1.6, 4.9) in women who didn't breast feed. CONCLUSIONS: This analysis found that there's potential benefit of BF in the prevention of DM among women who had GDM. This result adds to the already known important benefits of BF and more women should be encouraged to BF.
PDB98 assessmenT of a frencH enDocrinologisT elecTronic meDical recorD DaTaBase for Use in oBservaTional sTUDies
Hellard C, Jouaville SL, Pilet S, Meihoc A Cededim Strategic Data, Boulogne-Billancourt, France OBJECTIVES: Most endocrine disorders are chronic diseases that need life-long care. Some of the most common endocrine diseases include diabetes mellitus, hypothyroidism and metabolic syndrome. Although most of the patients suffering of these diseases are followed by their primary care physician, definite diagnosis, initiation/change of treatment and chronic care of the disease is ensured by the endocrinologist. The objective of this study was to evaluate an endocrinologist electronic medical record (EMR) database to assess its feasibility for use in observational studies. METHODS: We analyzed de-identified patient data from Longitudinal Patient Database (LPD) Endocrinologist panel, including endocrinologists from 2013-2014. Comprehensiveness and completeness of each variable by visit was evaluated. Characteristics of physicians and patient population were compared to published sources. RESULTS: There were 77 243 visits by 34 492 active patients (= 1 visit per year) to 40 physicians. Completeness of each variable by visit ranked from 100% to 27% for sex, age and laboratory results. Most of these patients (73%) were female. Analysis of diagnosis associated to visits revealed that 32 % were related to diabetes, while 32% and 9% were related to thyroid disorders and obesity respectively. Among diabetic patients, 50% were female, and 74% had type 2 diabetes. An average BMI of 30 and HbA1C of 7.4% was recorded. Among treated patients 38% received sulfonylureas and 59 % biguanides. A third of the patients (34%) received one, another third (33%) received two, and another third (33%) three or more anti-diabetic treatments (including insulin). Insulin was prescribed, alone or in combination, in 36% of cases. The comparison of these data with literature is presented. CONCLUSIONS: This panel is still new and needs further validation studies. Good agreement with published data suggests this may be a valuable tool to support observational studies. OBJECTIVES: Sulfonylureas (SU) are a widely-prescribed class of oral medications used to treat type 2 diabetes mellitus and are known to cause hypoglycemic events (HE) and weight gain. In this survey, we aimed to identify reasons reported by physicians for discontinuing (DC) or down-titrating (DT) SU therapy. METHODS: Primary care physicians (PCPs) and specialists (endocrinologists and diabetologists) were recruited from the AllGlobal panel, an actively managed, double opt-in panel of physicians. Participants were asked to rate their level of concern regarding potential reasons for DC or DT on a 7-point Likert scale (1= not at all concerned, 7= extremely concerned). In addition, physicians reviewed one chart each from a typical SU patient with DC or DT in the previous 6 months and 2 current SU patients without DC or DT in the previous 6 months to collect patient characteristics and medical history. RESULTS: 776 PCPs and 250 specialists participated, of whom 76% were male and 93% were aged 35 to 64. Physicians reported highest concern about HE
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